MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.090
-0.030
-1.42%
After Hours: 2.053 -0.037 -1.77% 16:38 07/07 EDT
OPEN
2.085
PREV CLOSE
2.120
HIGH
2.110
LOW
1.980
VOLUME
424.84K
TURNOVER
--
52 WEEK HIGH
6.20
52 WEEK LOW
0.8120
MARKET CAP
7.70M
P/E (TTM)
-0.3122
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.

EPS

NURO News

More
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
GlobeNewswire · 06/25 18:00
NeuroMetrix Shares Spike Higher Following News Co. Signed DPNCheck Collaboration Deal With Biomedix, No Terms Disclosed
Benzinga · 06/25 17:01
Edited Transcript of NURO earnings conference call or presentation 23-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/10 23:30
NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
GlobeNewswire · 06/10 18:00
NeuroMetrix Shares Spike To Session High, Up 42%, As Co. Issues Press Release Highlighting Launch Of Marketing Initiative Focusing On Chronic Knee With Quell 2.0 Wearable Pain Relief Device
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing
Benzinga · 06/10 17:10
BIDU, UAL among premarket gainers
Seeking Alpha - Article · 05/19 13:20
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kirkland's, Inc. (NASDAQ: KIRK) shares rose 54.3% to $1.30 in pre-market trading after the company said e-commerce demand was up 96% in the period since stores closed on March 19th.
Benzinga · 05/19 11:20
NeuroMetrix reports Q1 results
seekingalpha · 04/23 16:01

Industry

Medical Equipment, Supplies & Distribution
-0.86%
Healthcare Equipment & Supplies
-0.88%

Hot Stocks

Symbol
Price
%Change

About NURO

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
More

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.